Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2013-02-04 Proxy Solicitation & In…
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFINITIVE PROXY STATEMENT
Proxy Solicitation & Information Statement
2013-02-04 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a public offering of units consisting of common stock and warrants, detailing the terms of the offering, placement agent agreements, and related legal opinions. This is an update on the company's capital raising activities and financing structure. It is not a full financial report, earnings release, or management discussion, but rather a specific announcement about financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6197 characters) and detailed description support this classification with high confidence.
2013-01-30 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is titled 'Prospectus Supplement' and describes an offering of units consisting of common stock and warrants by Arrowhead Research Corporation. It includes detailed terms of the offering, pricing, placement agent fees, use of proceeds, risk factors, and legal disclaimers. The document is a formal offering prospectus supplement related to a securities issuance, which is a capital raising activity. It is not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full prospectus supplement, not just an announcement or brief notice.
2013-01-28 English
SABBY 13G-A ARWR 01.28.13
Major Shareholding Notification
2013-01-28 English
PRELIMINARY PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a Preliminary Prospectus Supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Arrowhead Research Corporation. It details the terms of an offering of units consisting of common stock and warrants, placement agent fees, use of proceeds, risk factors, and other offering-related information. This type of document is a capital raising disclosure, specifically a prospectus supplement for a securities offering, which fits the category of Capital/Financing Update filings. It is not an annual or quarterly report, earnings release, or any other type of report or announcement defined in the other categories. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is a full offering document, not just an announcement or a brief notice.
2013-01-25 English
SC 13G/A1
Major Shareholding Notification
2013-01-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.